-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
-POWERbody® powerful antibody integrates SAFEbody® precision masking technology, designed to greatly improve efficacy on the basis of ensuring drug safety
- Data demonstrate that safe, robust and durable immunotherapy targeting solid tumors can be achieved by covering and combining different mechanisms of action and pathways in the cancer immune cycle
Suzhou, China and San Diego, U.
In the poster session, Zhongtianyan will present the preclinical data of the company's three highly differentiated, potentially best-in-class, IND-enabling drug candidates (ADG138, ADG206 and ADG153), as well as the company's tailored dual drug candidates.
Details of the poster presentation include:
- Abstract Title: ADG138, a Novel HER2×CD3 POWERbody? Potent Antibody Combining Bispecific TCE with Precision Masking to Control Cytokine Release Syndrome and Off-target Toxicity of Monotherapy and Combination Therapy in HER2-expressing Solid Tumors
Dr.
About Tianyan Pharmaceutical
Tianyan Pharmaceutical (Nasdaq: ADAG) is a platform-driven clinical product development stage biopharmaceutical company with independent platform outputs.
For more information, please visit: https://investor.
SAFEbody ® is a registered trademark of Tianyan in the United States, China, Australia, Japan, Singapore and the European Union
Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding preclinical studies of ADG138, ADG206, ADG153G-1 and bispecific potent antibodies targeting CD28, the potential impact of the results of the preclinical studies of these antibodies, and the advancement of Tianyan Pharmaceuticals and anticipated clinical development, regulatory milestones, and commercialization of Tianyan's pipeline product candidates